Integration Site Analysis: An Innovative Method For Faster, More Certain Clone Selection & Genetic Stability Testing
This webinar will provide information on the new integration site analysis assay PathoQuest has launched. The assay uses Cas9 targeted DNA cleavage combined with nanopore sequencing technology to comprehensively sequence the junction site. This assay is a better alternative than Sanger, karyology, or Southern blot and is relevant for:
- Monoclonal antibodies & recombinant proteins: clone selection and genetic stability testing.
- Cell therapy: lot release testing
- Targeted Locus Amplification (TLA)
- Cultivated meat: clone selection and genetic stability testing.
Prof. Nicole Borth, PhD
Department of Biotechnology
Universität für Bodenkultur (BOKU)
Vienna, Austria
Colette Côté, PhD
Chief Scientific & Portfolio Officer
PathoQuest
Wayne, Pennyslvania
Chief Scientific & Portfolio Officer
PathoQuest
Wayne, Pennyslvania
Dan Fordham
Director, Strategic Product Management
Oxford Nanopore Technologies
Oxford, England
DATE: Friday, October 13, 2023
TIME:
5 pm CEST (EU)
4 pm BST (UK)
11 am Eastern Time
8 am Pacific Time
DATE: Monday, October 23, 2023
TIME:
11 am CEST (EU)
10 am BST (UK)